This content is from: Patents

Oxford tech transfer chief: ‘It’s been the most intense year’

In an exclusive interview, Adam Stoten of Oxford University Innovation explains why his team partnered with AstraZeneca on a COVID vaccine – and what made the deal unique

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial